NYSEAMERICAN:VNRX VolitionRX Q3 2026 Earnings Date & Estimates $0.18 +0.00 (+2.58%) Closing price 10/26/2026 04:10 PM EasternExtended Trading$0.18 +0.01 (+3.58%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. VolitionRX is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call DateNovember 13, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from VolitionRX in Q3 2026VolitionRX is expected to post earnings of -$0.35 per share on revenue of $706 thousand. VolitionRX last reported on August 13, 2026, posting -$0.85 per share and missing the -$0.5675 consensus estimate. VolitionRX has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.35Expected Revenue$706 thousandRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.85 (Missed by -$0.2825)Last Quarter Revenue$398.66 thousandEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ2 2024 Earnings Report VolitionRX Q3 2026 Earnings FAQ When does VolitionRX report Q3 2026 earnings? VolitionRX (NYSEAMERICAN:VNRX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is VolitionRX's Q3 2026 earnings call? VolitionRX's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for VolitionRX? Analysts expect VolitionRX to post earnings of -$0.35 per share for Q3 2026. How much revenue is VolitionRX expected to report? The consensus revenue estimate for VolitionRX is $706 thousand for Q3 2026. VolitionRX Earnings HeadlinesVolitionRX LtdOctober 20, 2026 | money.usnews.comVolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average - What's Next?October 17, 2026 | americanbankingnews.comA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright.October 27 at 1:00 AM | True Market Insiders (Ad)VolitionRx consensus price target decreased by 17.44% to $13.89October 2, 2026 | msn.comVolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in FranceSeptember 17, 2026 | prnewswire.comVolitionRx Participates in Launch of DETECSEPS Program in FranceSeptember 17, 2026 | prnewswire.comSee More VolitionRX Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRX and other key companies, straight to your email. Email Address About VolitionRXVolitionRX (NYSEAMERICAN:VNRX) Ltd. is a biotechnology company developing blood-based diagnostic tests designed to help detect and monitor cancer and other diseases. Its technology platform, Nu.Q, measures nucleosomes—small fragments of DNA and associated proteins released into the bloodstream during cell death—which may provide information about disease activity. The company’s products include Nu.Q Vet, a suite of blood tests developed for veterinary oncology. The tests are intended to support cancer screening, diagnosis, and monitoring in dogs and other companion animals. VolitionRx is also developing human applications of its technology, including tests aimed at cancer detection, treatment monitoring, and the identification of neutrophil extracellular traps, or NETs, which are associated with inflammation and certain diseases. VolitionRx was established in 2010 and operates internationally through subsidiaries and research activities in the United States and Europe. The company has focused on advancing and commercializing its Nu.Q platform through collaborations and distribution relationships in both veterinary and human healthcare markets. Cameron Reynolds has served as the company’s chief executive officer and president.View VolitionRX ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
